Finerenone (Kerendia®). HTA ID: 23077

Assessment Status Rapid Review Complete
HTA ID 23077
Drug Finerenone
Brand Kerendia®
Indication Finerenone (Kerendia®) is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes (T2D) in adults.
Assessment Process
Rapid review commissioned 20/12/2023
Rapid review completed 23/01/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that finerenone not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.